Key facts
- This page summarizes Stewart Appelrouth's Form 4 filing for AIM ImmunoTech Inc. (AIMI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 03 Jan 2025, 16:35.
Stewart Appelrouth - 31 Dec 2024 Form 4 Insider Report for AIM ImmunoTech Inc. (AIMI)
- Reporting relationship
- Director
- Issuer ticker
- AIMI
- Reported as of
- 31 Dec 2024
- Net transaction value
- +$1,736
- SEC form
- 4
- Accepted by SEC
- 03 Jan 2025, 16:35:19 UTC
- Prior SEC filing
- 17 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stewart Appelrouth
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stewart Appelrouth filed Form 4 for AIM ImmunoTech Inc. (AIMI) on 03 Jan 2025.
Change
- Previous filing in this sequence was filed on 17 Dec 2024.
- Current net transaction value: +$1,736.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AIM
transaction
Common Stock
Award
- Transaction value
- $1,736
- Shares
- +8,768
- Change %
- +2.3%
- Price
- $0.1980
- Shares after
- 388,729
- Date
- 31 Dec 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Stewart Appelrouth is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
The shares acquired on the Transaction Date were issued in lieu of director compensation pursuant to the issuer's Cash Conservation Plan.